Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Daniel L. COURY |
Documents disponibles écrits par cet auteur (4)
Faire une suggestion Affiner la recherche
Brief report: Measures of effectiveness for single-question sleep problem screeners in children with autism spectrum disorder / Alison R. MARVIN in Research in Autism Spectrum Disorders, 80 (February 2021)
[article]
Titre : Brief report: Measures of effectiveness for single-question sleep problem screeners in children with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Alison R. MARVIN, Auteur ; Daniel L. COURY, Auteur ; Beth A. MALOW, Auteur ; J. Kiely LAW, Auteur ; Amanda E. BENNETT, Auteur Article en page(s) : p.101699 Langues : Anglais (eng) Mots-clés : Autism Sleep Composite Sleep Disturbance Index Screening Primary care Psychometrics Index. décimale : PER Périodiques Résumé : Background Although screening for sleep problems in children with ASD is recommended, primary care providers generally ask parents a single, high-level screening question about their child’s sleep. Can this capture whether a child has severe sleep problems? Method Parents of children with ASD ages 3–17 years recruited from a validated and verified US-based autism research registry completed an online survey on co-occurring conditions, including “degree of sleep problems”. The Composite Sleep Disturbance Index (CSDI) and its question on “parent satisfaction with current sleep pattern” were also incorporated. Results 610 parent/child dyads were analyzed. 377 (62%) children had severe sleep problems per CSDI; 215 (57%) were parent-rated with Moderate/Severe sleep problems. 219 (93%) of 233 children without a severe sleep problem on CSDI were parent-rated as having None/Mild sleep problems. 94% with Moderate/Severe sleep problems per parents had severe sleep problems per CSDI. However, 15% of those whose parents rated as None had a severe sleep problem. 200 (33%) children had a Mild sleep problem rating; of these, 134 (67%) had CSDI severe sleep problem and 66 (33%) did not. Conclusions A single question about sleep was good at classifying severe vs. non-severe sleep problems in children with ASD, especially with extreme responses. However, a single question was poor at classifying intermediate/non-extreme responses, and a significant number of children with severe sleep problems were missed. Screening with a short, validated questionnaire or asking more probing questions would assist in diagnosing most children with sleep problems. Parents may benefit from sleep education. En ligne : https://doi.org/10.1016/j.rasd.2020.101699 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=438
in Research in Autism Spectrum Disorders > 80 (February 2021) . - p.101699[article] Brief report: Measures of effectiveness for single-question sleep problem screeners in children with autism spectrum disorder [Texte imprimé et/ou numérique] / Alison R. MARVIN, Auteur ; Daniel L. COURY, Auteur ; Beth A. MALOW, Auteur ; J. Kiely LAW, Auteur ; Amanda E. BENNETT, Auteur . - p.101699.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 80 (February 2021) . - p.101699
Mots-clés : Autism Sleep Composite Sleep Disturbance Index Screening Primary care Psychometrics Index. décimale : PER Périodiques Résumé : Background Although screening for sleep problems in children with ASD is recommended, primary care providers generally ask parents a single, high-level screening question about their child’s sleep. Can this capture whether a child has severe sleep problems? Method Parents of children with ASD ages 3–17 years recruited from a validated and verified US-based autism research registry completed an online survey on co-occurring conditions, including “degree of sleep problems”. The Composite Sleep Disturbance Index (CSDI) and its question on “parent satisfaction with current sleep pattern” were also incorporated. Results 610 parent/child dyads were analyzed. 377 (62%) children had severe sleep problems per CSDI; 215 (57%) were parent-rated with Moderate/Severe sleep problems. 219 (93%) of 233 children without a severe sleep problem on CSDI were parent-rated as having None/Mild sleep problems. 94% with Moderate/Severe sleep problems per parents had severe sleep problems per CSDI. However, 15% of those whose parents rated as None had a severe sleep problem. 200 (33%) children had a Mild sleep problem rating; of these, 134 (67%) had CSDI severe sleep problem and 66 (33%) did not. Conclusions A single question about sleep was good at classifying severe vs. non-severe sleep problems in children with ASD, especially with extreme responses. However, a single question was poor at classifying intermediate/non-extreme responses, and a significant number of children with severe sleep problems were missed. Screening with a short, validated questionnaire or asking more probing questions would assist in diagnosing most children with sleep problems. Parents may benefit from sleep education. En ligne : https://doi.org/10.1016/j.rasd.2020.101699 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=438 Diagnosis and Assessment of Autism Spectrum Disorders: A Medical Perspective / Daniel L. COURY
Titre : Diagnosis and Assessment of Autism Spectrum Disorders: A Medical Perspective Type de document : Texte imprimé et/ou numérique Auteurs : Daniel L. COURY, Auteur Année de publication : 2011 Importance : p.1283-1294 Langues : Anglais (eng) Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=140 Diagnosis and Assessment of Autism Spectrum Disorders: A Medical Perspective [Texte imprimé et/ou numérique] / Daniel L. COURY, Auteur . - 2011 . - p.1283-1294.
Langues : Anglais (eng)
Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=140 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire Medical comorbidities in autism spectrum disorder / Jennifer R. WALTON
Titre : Medical comorbidities in autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jennifer R. WALTON, Auteur ; Daniel L. COURY, Auteur Année de publication : 2015 Importance : p.33-41 Langues : Anglais (eng) Mots-clés : Maladies gastro-intestinales Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=271 Medical comorbidities in autism spectrum disorder [Texte imprimé et/ou numérique] / Jennifer R. WALTON, Auteur ; Daniel L. COURY, Auteur . - 2015 . - p.33-41.
Langues : Anglais (eng)
Mots-clés : Maladies gastro-intestinales Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=271 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder / Sarah A. KEIM in Journal of Autism and Developmental Disorders, 52-12 (December 2022)
[article]
Titre : Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur Année de publication : 2022 Article en page(s) : p.5342-5355 Langues : Anglais (eng) Mots-clés : Child Child, Preschool Humans Autism Spectrum Disorder/drug therapy Biomarkers Dietary Supplements Double-Blind Method Fatty Acids, Omega-3/therapeutic use Fatty Acids, Omega-6/therapeutic use Interleukin-2/metabolism Autism spectrum disorder Il-2 Inflammation Omega-3 fatty acids Omega-6 fatty acids Young child the content of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Nordic Naturals provided the investigational product at no cost and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither the study sponsors nor product providers had a role in the study design the collection, analysis, and interpretation of data writing of this report or the decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6Â years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90Â days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40Â mol% for EPA and 1.62Â mol% for DHA) and reduced IL-2 levels compared to placebo (-Â 0.17Â pg/mL, 95% CI -Â 0.31, -Â 0.02, d=-Â 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489
in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355[article] Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur . - 2022 . - p.5342-5355.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355
Mots-clés : Child Child, Preschool Humans Autism Spectrum Disorder/drug therapy Biomarkers Dietary Supplements Double-Blind Method Fatty Acids, Omega-3/therapeutic use Fatty Acids, Omega-6/therapeutic use Interleukin-2/metabolism Autism spectrum disorder Il-2 Inflammation Omega-3 fatty acids Omega-6 fatty acids Young child the content of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Nordic Naturals provided the investigational product at no cost and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither the study sponsors nor product providers had a role in the study design the collection, analysis, and interpretation of data writing of this report or the decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6Â years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90Â days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40Â mol% for EPA and 1.62Â mol% for DHA) and reduced IL-2 levels compared to placebo (-Â 0.17Â pg/mL, 95% CI -Â 0.31, -Â 0.02, d=-Â 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489